Search results
Results From The WOW.Com Content Network
Genentech is a pioneering biotechnology company founded in 1976 by Robert Swanson and Herbert Boyer. It became an independent subsidiary of Roche in 2009 and has developed several blockbuster drugs, such as Avastin, Herceptin, Rituxan, and Lucentis.
Genentech is committed to people having access to our medicines. Genentech Access Solutions is a team of more than 350 Genentech employees who help those who need our medicines.
McKesson is a US-based health care company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. It is the ninth-largest company in the US and the nation's largest health care company, with a history dating back to 1833.
Efalizumab was a monoclonal antibody used to treat psoriasis, but was withdrawn in 2009 due to serious side effects such as brain infections. It bound to CD11a, an adhesion molecule that regulates lymphocyte activation and migration.
IQVIA is a Fortune 500 and S&P 500 company that provides biopharmaceutical development, consulting and commercial outsourcing services. It was formed in 2016 by the merger of Quintiles and IMS Health, two leading providers of healthcare data and analytics.
For premium support please call: 800-290-4726
David V. Goeddel (born 1951) is an American molecular biologist who, employed at the time by Genentech, successfully used genetic engineering to coax bacteria into creating synthetic human insulin, human growth hormone, and human tissue plasminogen activator (tPA) for use in therapeutic medicine.
As of April 2020, the company's subsidiaries include: Affivant; Covant; Datavant; Genevant, created to work on RNA-based therapeutics [33]; Hemovant; Immunovant, launched in July 2018 to develop therapies for autoimmune diseases, with lead candidate IMVT-1401 being developed for the treatment of myasthenia gravis, Graves' ophthalmopathy and warm antibody autoimmune hemolytic anemia [34]